A Phase II Study of Olaparib in Breast Cancer Patients: Biological Evaluation from a ‘Window of Opportunity’ Trial
Giandomenico Roviello(University of Florence), Daniele Generali(University of Trieste), Chiara Senti(Istituti Ospitalieri di Cremona), A. Cocconi(Istituti Ospitalieri di Cremona), Maria Rosa Cappelletti(University of Trieste), Giovanni Allevi(Istituti Ospitalieri di Cremona), Francesca Gussago(Istituti Ospitalieri di Cremona), Sergio Aguggini(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Martina Dester(Istituti Ospitalieri di Cremona), Laura Zanotti(Istituti Ospitalieri di Cremona), Andrea Ravelli(The University of Texas MD Anderson Cancer Center), Manuela Milani(Humanitas University), Angela Gobbi(Istituti Ospitalieri di Cremona), Alberto Bottini(University of Genoa)
Cited by 10
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268